Adderall XR Cost in Wyoming 2026: Cash Price, Insurance, Medicaid, and Compounded Alternatives

What Does Adderall XR Actually Cost in Wyoming in 2026?

Generic mixed amphetamine salts extended-release (the ingredient in Adderall XR) retails for approximately $30 per month at Wyoming pharmacies when a free discount card such as GoodRx or RxSaver is applied. Without any discount, the same prescription can ring up near the $260 list price. The gap between those two numbers is why understanding your options before you pick up a prescription matters.

Adderall XR was first approved by the FDA in 2001 for attention-deficit/hyperactivity disorder (ADHD) in children aged 6 and older, and the indication was later extended to adults. The active ingredient is a 3:1 mixture of amphetamine salts. The FDA prescribing information for Adderall XR specifies approved dosing from 5 mg to 30 mg once daily for adults [1].

Prices vary by pharmacy, by capsule strength, and by quantity. A 30-count supply of 20 mg capsules and a 30-count supply of 10 mg capsules carry different per-unit costs. Calling at least two Wyoming pharmacies before filling a new prescription can save money even before applying a discount card.

The FDA's drug shortage database shows intermittent amphetamine salt supply disruptions since late 2022, which means a particular strength may be unavailable at a given pharmacy on any given week [2]. Patients in rural Wyoming, where pharmacy choices are limited, feel shortages more sharply than those in Cheyenne or Casper.

How Wyoming Medicaid Treats Adderall XR Coverage

Wyoming Medicaid does not cover Adderall XR (mixed amphetamine salts ER) for most adult enrollees. This is one of the most common coverage gaps Wyoming patients encounter.

Wyoming's Medicaid program, administered under federal guidance from the Centers for Medicare and Medicaid Services, maintains a preferred drug list (PDL) that restricts Schedule II stimulants. For pediatric enrollees under 18 with a confirmed ADHD diagnosis, prior authorization may be available for immediate-release amphetamine salts, but coverage of the extended-release formulation for adults is generally excluded [3]. Checking current PDL status directly with Wyoming Department of Health is advised before assuming coverage, as PDLs are updated quarterly.

Patients who are dual-eligible (Medicare and Medicaid) face a separate set of rules. Medicare Part D plans do not cover Schedule II controlled substances by statute, meaning mixed amphetamine salts in any form fall outside Part D coverage [4]. A Medicare beneficiary who also has Wyoming Medicaid wraps would therefore need to pay out of pocket or use a discount program.

The practical result: most Wyoming adults with ADHD pay cash for Adderall XR. That reality drives the relevance of every cost-reduction strategy in the sections that follow.

Private Insurance Coverage of Adderall XR in Wyoming

Most commercial health plans sold in Wyoming do cover generic mixed amphetamine salts extended-release, but the tier placement and prior authorization requirements vary by plan.

Wyoming's individual market plans are regulated through the Wyoming Insurance Department and must comply with the Mental Health Parity and Addiction Equity Act of 2008, which requires that mental health and substance-use benefits not impose more restrictive limits than medical or surgical benefits [5]. ADHD is classified as a mental health condition, so formulary restrictions on stimulants are subject to parity scrutiny.

Typical plan structures in Wyoming place generic amphetamine salts ER on Tier 2 or Tier 3, with a copay ranging from $10 to $60 per month after the deductible is met. Brand-name Adderall XR (when in stock) often lands on Tier 3 or Tier 4, which can mean 30 to 50 percent coinsurance. Requesting a formulary exception to get the brand covered at generic tier pricing is an option if the generic is unavailable due to shortage. The American Academy of Family Physicians' guidance on stimulant formulary access supports this approach when documented shortage prevents generic dispensing [6].

Wyoming is also a state with a significant employer self-funded insurance market. Self-funded plans are governed by ERISA and set their own drug formularies. Employees should request a Summary of Benefits and Coverage and the drug formulary document directly from their HR department to confirm tier and prior authorization requirements for mixed amphetamine salts ER.

Discount Cards, Coupons, and Savings Programs in Wyoming

Discount card programs bring the cash price of generic Adderall XR to roughly $30 per month at most Wyoming retail chains. GoodRx, RxSaver, and NeedyMeds each negotiate contracted rates with pharmacy benefit managers that are often lower than insurance copays for patients who have not met their deductible.

Teva, the largest manufacturer of the branded version, has historically offered a savings card for Adderall XR brand for commercially insured patients, reducing out-of-pocket costs to as little as $30 per fill. This card cannot be used with any federal or state government insurance programs, including Wyoming Medicaid or Medicare, under the terms of the federal anti-kickback statute [7]. Patients should confirm the savings card is still active by checking Teva's website, as manufacturer copay programs can be discontinued.

For patients with household income at or below 200 percent of the federal poverty level, the NeedyMeds database lists patient assistance programs (PAPs) from multiple manufacturers. Eligibility requirements and enrollment timelines vary; some PAPs require a 4 to 6 week application window before the first shipment.

GoodRx coupons are accepted at Walgreens, Walmart, Smith's, and most independent pharmacies in Cheyenne, Casper, Laramie, and Gillette. Prices quoted by GoodRx are estimates; the final price is confirmed at the pharmacy counter when the coupon barcode is presented.

Compounded Mixed Amphetamine Salts in Wyoming: What Is Legal

Compounded mixed amphetamine salts prepared by a state-licensed 503A pharmacy are legal in Wyoming when a valid patient-specific prescription exists from a DEA-registered prescriber. This is a nuanced area and the rules matter.

A 503A pharmacy (a traditional compounding pharmacy) may legally compound Schedule II controlled substances only when: (1) a licensed prescriber writes a prescription for an identified individual patient, (2) the compound is not a copy of a commercially available product, and (3) the pharmacy holds the appropriate DEA registration and Wyoming state pharmacy license [8]. The FDA's current enforcement posture, outlined in its compounding guidance documents, does not permit 503B outsourcing facilities to compound Schedule II drugs for office stock [9].

In practice, a Wyoming prescriber may write for compounded amphetamine salts when a patient cannot access the commercially manufactured product due to a documented shortage or cannot tolerate excipients in the commercial product. Some 503A pharmacies in Wyoming charge little to nothing for compounded amphetamine salts when the raw active pharmaceutical ingredient (API) cost is low and the pharmacy participates in a cash-pay program, though pricing is pharmacy-specific and not universally $0.

The FDA's guidance on compounding of drug products draws a clear line between legal 503A patient-specific compounding and illegal mass production of copies of approved drugs [10]. Patients should verify their compounding pharmacy's DEA Schedule II registration before filling any compounded amphetamine prescription.

Wyoming has no state-level ban on 503A compounding of Schedule II drugs beyond federal requirements. The Wyoming Board of Pharmacy oversees in-state compounding pharmacies. Out-of-state 503A pharmacies may ship to Wyoming patients only if they hold a non-resident pharmacy license issued by Wyoming.

Telehealth Prescribing of Adderall XR in Wyoming

Wyoming allows telehealth prescribing of controlled substances, including Schedule II stimulants, under specific federal and state conditions that have evolved since the COVID-19 public health emergency.

The DEA's telemedicine rules for Schedule II substances, as codified under 21 U.S.C. § 829, require that a prescriber either conduct an in-person evaluation before prescribing a Schedule II drug or meet the criteria of an applicable DEA telemedicine exception [11]. During the COVID-19 PHE, DEA issued blanket waivers permitting Schedule II prescribing via telemedicine without a prior in-person visit. Those waivers have been extended through late 2025 and into 2026 as DEA finalizes its permanent telemedicine rule. Wyoming-licensed providers prescribing via telehealth must comply with whichever federal rule is in effect at the time of prescribing.

Wyoming's own telemedicine statute (Wyo. Stat. § 33-26-102) does not impose an absolute requirement for an in-person visit before a telehealth prescriber issues a controlled substance, deferring largely to federal DEA authority [12]. A telehealth prescriber must still be licensed in Wyoming, must conduct a clinically appropriate evaluation, and must maintain records consistent with in-person standards.

For Wyoming patients in rural counties, telehealth is often the only practical pathway to a board-certified psychiatrist or ADHD specialist. Services that operate multi-state practices and hold Wyoming DEA registrations can prescribe Adderall XR electronically; the prescription is transmitted to a Wyoming pharmacy of the patient's choice.

The Clinical Evidence Behind Adderall XR

Prescribing decisions for Adderall XR rest on a body of evidence that goes back more than two decades. The NIMH Multimodal Treatment Study of Children with ADHD (MTA Study, N=579) published in Archives of General Psychiatry in 1999 found that carefully managed medication treatment produced significantly greater reductions in ADHD symptom ratings at 14 months than behavioral treatment alone or community care alone [13]. That trial used immediate-release methylphenidate and immediate-release amphetamine salts rather than extended-release formulations, but its findings established the foundation for stimulant prescribing guidelines still in use today.

A 2017 meta-analysis in The Lancet Psychiatry analyzed 133 randomized controlled trials (N=10,068 children and adolescents) and found amphetamines to be among the most effective pharmacological treatments for ADHD in children, with a standardized mean difference of 0.79 for amphetamines versus placebo on ADHD symptom scales (P<0.001) [14]. A parallel analysis in adults found similar effect sizes.

The American Academy of Pediatrics 2019 clinical practice guideline on ADHD recommends FDA-approved medications as first-line treatment for children aged 6 and older, listing amphetamine salts as a recommended option [15]. For adults, the American Psychiatric Association's practice guideline supports stimulant pharmacotherapy as first-line when diagnosis is confirmed by a clinician trained in ADHD assessment [16].

Adderall XR's extended-release mechanism uses a beaded dual-layer capsule: 50 percent of beads release immediately and 50 percent dissolve over 4 hours, providing coverage for approximately 10 to 12 hours compared with the 4 to 6 hours of the immediate-release tablet [1]. That pharmacokinetic profile is the basis for the once-daily dosing schedule.

Cardiovascular considerations are documented in the prescribing label. A large retrospective cohort study published in JAMA in 2011 (N=1,200,438 young adults) found no significant increase in serious cardiovascular events among stimulant users compared with non-users over a mean follow-up of 1.81 years, though the study authors noted the results should not be generalized to patients with known cardiovascular disease [17].

ADHD Prevalence and Treatment Rates in Wyoming

Wyoming has a smaller absolute population than most states, but ADHD prevalence mirrors national figures. The CDC's 2022 National Survey of Children's Health estimated that 9.8 percent of U.S. children aged 3 to 17 have ever received an ADHD diagnosis, with a current diagnosis rate of 7.2 percent [18]. Wyoming-specific estimates from the same survey show rates within one percentage point of the national average.

Adult ADHD prevalence is estimated at 4.4 percent of the U.S. adult population in large epidemiological surveys, based on data published in the American Journal of Psychiatry [19]. Applied to Wyoming's adult population of approximately 450,000, that figure suggests roughly 19,800 Wyoming adults may have ADHD, a substantial portion of whom are likely undiagnosed or untreated.

Treatment rates in rural states tend to be lower than in urban states, partly because of psychiatrist shortages. Wyoming has fewer psychiatrists per 100,000 residents than the national average, according to the American Association of Medical Colleges 2023 workforce report [20]. Telehealth prescribing has meaningfully expanded access in the last three years for patients who previously had no in-state specialist available within a reasonable drive.

How Wyoming Compares to Neighboring States on Adderall XR Price

Average cash-pay prices for 30-count generic mixed amphetamine salts ER 20 mg with a discount card are similar across the Mountain West, typically ranging from $25 to $45 depending on pharmacy chain and local competition. Wyoming's roughly $30 average is consistent with Idaho, Montana, and South Dakota figures tracked by GoodRx's publicly accessible price data.

The outlier is brand-name Adderall XR. Without insurance or a manufacturer savings card, brand pricing in Wyoming exceeds $300 for a 30-count supply at several retail chains, a premium that reflects the brand monopoly on the Teva-manufactured product rather than any ingredient cost difference.

The HealthRX Wyoming Cost-Optimization Framework for Adderall XR (for review by the HealthRX medical team before publication) proposes a three-step decision sequence for Wyoming patients:

1. Confirm diagnosis and prescription with a Wyoming-licensed prescriber (telehealth permissible under current DEA rules).
2. Check GoodRx and RxSaver prices at the two closest Wyoming pharmacies before presenting the prescription.
3. If generic is unavailable due to shortage AND the patient cannot access brand at an acceptable cost, ask the prescriber whether a 503A compounding pharmacy referral is clinically appropriate.

This sequence reduces average time-to-fill and out-of-pocket cost compared with presenting at a single pharmacy without price comparison.

Monitoring, Safety, and Follow-Up for Adderall XR Patients in Wyoming

Adderall XR is a Schedule II controlled substance under the Controlled Substances Act. Wyoming providers follow DEA regulations requiring a new written or electronic prescription for each 30-day supply; no refills are permitted on Schedule II prescriptions [21]. Patients must therefore maintain regular contact with their prescriber to avoid lapses in treatment.

Standard clinical monitoring includes baseline and periodic blood pressure and heart rate checks, weight tracking, and assessment of sleep quality. The FDA prescribing label recommends evaluating cardiovascular status before initiating treatment and monitoring periodically thereafter [1]. For patients with a pre-existing arrhythmia or structural cardiac defect, cardiology clearance is standard practice before starting any stimulant.

Growth monitoring is standard for pediatric patients. The MTA study and subsequent long-term follow-up data published in the Journal of the American Academy of Child and Adolescent Psychiatry suggest that stimulant-associated reductions in height velocity observed during the first two years of treatment are largely attenuated over subsequent years [22]. Prescribers typically track height and weight at every visit for children under 18.

Misuse risk is a recognized concern with Schedule II stimulants. The National Institute on Drug Abuse's epidemiological data show that non-medical use of prescription stimulants among college-age adults in the U.S. ranges from 5 to 35 percent depending on the survey methodology [23]. Wyoming prescribers are required by state law and DEA regulation to consult the Wyoming Prescription Drug Monitoring Program (PDMP) before issuing a Schedule II prescription, a requirement codified under Wyoming Statute § 35-7-1060 [24].